Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Vaccine trials protect against 80% meningitis strains

  • Comment

Trials for a new meningitis vaccine have produced “exciting” results that are encouraging signs for combating the disease in future.

Currently, there is no jab to safeguard against strains of meningitis B, which covers around 90% of cases in the UK.

It is a deadly form of the disease that can sometimes kill babies and toddlers in under four hours.

But new data on a 4CMenB vaccine has revealed that it can protect against an estimated 80% of 1,000 meningitis B strains from across Europe.

Results from 1,800 children discovered that it worked well both on its own and with vaccines for other strains of the disease.

Further research on 1,500 toddlers discovered that it offers protection when given as a booster jab, while another demonstrated immune response in teenagers.

Meningitis UK said the new vaccine could lead to thousands of lives being saved in the future.

Chief executive Steve Dayman said: “This data is a very positive step in the fight to eradicate meningitis B, which is the biggest killer of all types of meningitis in the UK.

“This vaccine is the first of its kind and has the potential to save thousands of lives.”

You can discuss this further on our Nursing Times forum, connect with your peers!

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs